title: [New study of selective COX-2 inhibitors. Protecting the stomach while risking the heart? (interview by Dr. Beate Schumacher)].
authors.forename: H
authors.initials: H
authors.lastname: Zeidler
mesh_terms: D000068579:Celecoxib; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects*; D008565:Membrane Proteins; D009203:Myocardial Infarction / Q000139:chemically induced*; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D012307:Risk Factors; D013276:Stomach Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D013450:Sulfones
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib